Category: Include on Menu
-
Gold Advances as Dollar Weakens Further; Iran Talks Remain in Focus
Gold prices moved higher during Asian trading on Thursday, supported by continued softness in the U.S. dollar, while investors kept a close watch on the possibility of renewed ceasefire discussions between Washington and Tehran. The metal remained near a one-month high reached in the previous session, as expectations of easing tensions in the Iran conflict…
-
Markets Watch Iran Peace Talks as Futures Rise; TSMC Delivers Strong Results: Dow Jones, S&P, Nasdaq, Wall Street Futures
U.S. equity futures moved higher on Thursday as investors tracked developments around a possible new round of negotiations between Washington and Tehran. Efforts continue to extend a temporary ceasefire and restore shipping through the Strait of Hormuz. Oil prices edged up but remained below the $100 per barrel mark. Meanwhile, China reported stronger-than-expected economic growth…
-
Markets in Motion: sentiment resets as rotation picks up
Sentiment cools as new leadership starts to emerge In this week’s Markets in Motion, Bruce Campbell highlights how sentiment has dropped following geopolitical tension in Iran, while fund manager cash levels have climbed back into a more neutral range. That matters because extremely low cash levels had previously signalled that markets were vulnerable to a…
-
S&P 500 Notches Fresh Record as Tech and Bank Earnings Power Wall Street Higher
U.S. stocks finished Wednesday on a split but broadly upbeat note, with the S&P 500 and Nasdaq Composite pushing higher on the back of strong bank earnings, renewed enthusiasm for artificial intelligence infrastructure, and a sharp pullback in oil prices following an easing of Middle East tensions. The Dow Jones Industrial Average was the day’s…
-
CrowdStrike Earns Top Customer Recognition in Gartner SIEM Report
CrowdStrike (NASDAQ:CRWD) has been named a Customers’ Choice in the 2026 Gartner Peer Insights “Voice of the Customer” report for Security Information and Event Management (SIEM), reflecting strong user feedback and high satisfaction levels. The company said it received the highest number of five-star ratings and the most verified reviews among vendors in the report,…
-
Allogene Publishes Promising ALLO-329 Data in Nature Communications
Allogene Therapeutics (NASDAQ:ALLO) said new pre-clinical data for its investigational CAR-T therapy ALLO-329 have been published in Nature Communications, highlighting a dual-targeting approach aimed at treating autoimmune diseases. ALLO-329 is an allogeneic, off-the-shelf CAR-T candidate designed to target both CD19-positive B cells and CD70-positive activated T cells, two key drivers of autoimmune conditions. The data…
-
Allied Gaming Resolves Legal Dispute and Outlines Shift Toward AI and Digital Assets
Allied Gaming & Entertainment Inc. (NASDAQ:AGAE) said it has reached a settlement with Knighted Pastures LLC, bringing all related legal matters to a close, according to a company statement. Following the resolution, the company is turning its attention to new strategic initiatives, including plans to launch its cryptocurrency, Allied Coin, in 2026, subject to regulatory…
-
La Rosa Holdings Takes Full Control of Orlando Brokerage Unit
La Rosa Holdings Corp. (NASDAQ:LRHC) announced it has acquired the remaining 49% stake in La Rosa Realty Orlando LLC, bringing the operation fully under its ownership. The Orlando-based business, which provides residential and commercial brokerage services along with agent coaching and support, generated approximately $3.3 million in revenue and more than $0.3 million in gross…
-
Lunai Bioworks Unit Signs Preliminary Deal with Geneial on Rare Disease Data Collaboration
Lunai Bioworks (NASDAQ:LNAI) said its subsidiary BioSymetrics has entered into a letter of intent with Geneial to explore a collaboration focused on rare neurological conditions. The non-binding agreement aims to transform patient-generated information into structured datasets that can be used to support drug development and improve clinical trial recruitment. The initiative targets rare diseases, which…
-
Immutep Shares Surge After FDA Grants Orphan Drug Status to Cancer Therapy
Immutep (NASDAQ:IMMP) shares jumped sharply on Wednesday after the company announced that the U.S. Food and Drug Administration had granted Orphan Drug Designation (ODD) to eftilagimod alfa. Eftilagimod alfa is being developed as a treatment for soft tissue sarcoma (STS), a rare and complex group of cancers that arise in connective tissues such as muscle,…